Selected article for: "death toll and health care"
Author: Jeyaraman, Madhan; John, Albin; Koshy, Santhosh; Ranjan, Rajni; TalagavadiChannaiahAnudeep,; Jain, Rashmi; Swati, Kumari; Jha, Niraj Kumar; Sharma, Ankur; Kesari, Kavindra Kumar; Prakash, Anand; Nand, Parma; Jha, Saurabh Kumar; Reddy, P. Hemachandra
Title: Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19
  • Cord-id: w2ijv830
  • Document date: 2020_11_22
    • ID: w2ijv830
    Snippet: The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11thof March, 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with
    Document: The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11thof March, 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19.

    Search related documents:
    Co phrase search for related documents
    • action site and acute respiratory syndrome: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and liver cardiac: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and liver cardiac renal: 1
    • acute ards respiratory distress syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and low antiinflammatory: 1
    • acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
    • acute ards respiratory distress syndrome develop and adipose tissue: 1
    • acute ards respiratory distress syndrome develop and local inflammation: 1
    • acute inflammation and adipose tissue: 1, 2
    • acute inflammation and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute inflammation and low antiinflammatory: 1
    • acute inflammation and low immunogenicity: 1
    • acute lung injury and adipose tissue: 1, 2
    • acute lung injury and local inflammation: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver cardiac: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver cardiac renal: 1, 2, 3, 4
    • acute respiratory syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25